Tumor Cell Dormancy: Threat or Opportunity in the Fight against Cancer
Open accessThe DOI matches its Crossref record; 137 of the 140 references it cites were found in a registry or an index.
Abstract
Tumor dormancy, a clinically undetectable state of cancer, makes a major contribution to the development of multidrug resistance (MDR), minimum residual disease (MRD), tumor outgrowth, cancer relapse, and metastasis. Despite its high incidence, the whole picture of dormancy-regulated molecular programs is far from clear. That is, it is unknown when and which dormant cells will resume proliferation causing late relapse, and which will remain asymptomatic and harmless to their hosts. Thus, identification of dormancy-related culprits and understanding their roles can help predict cancer prognosis and may increase the probability of timely therapeutic intervention for the desired outcome. Here, we provide a comprehensive review of the dormancy-dictated molecular mechanisms, including angiogenic switch, immune escape, cancer stem cells, extracellular matrix (ECM) remodeling, metabolic reprogramming, miRNAs, epigenetic modifications, and stress-induced p38 signaling pathways. Further, we analyze the possibility of leveraging these dormancy-related molecular cues to outmaneuver cancer and discuss the implications of such approaches in cancer treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The loss of tissue integrity, carcinogenesis and further progress occurs as a consequence of reciprocal interactions between tumor cells with non-cellular (ECM) and cellular components of the TME [9, 10].”
From Tumor microenvironment complexity and therapeutic implications at a glance (2020) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, the ECM of distant organs can be remotely shaped into permissive/restrictive soils by soluble factors/CTCs/exosomes from primary tumors to facilitate the seeding of metastasizing cancer cells (See for review [9]).”
From Tumor microenvironment complexity and therapeutic implications at a glance (2020) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thus, they can serve as valuable prognostic, diagnostic, and biosensing tools to detect cancer cells that are clinically undetectable, and to make plans for timely and precise therapeutic interventions (Fig. 2e) [9].”
From Tumor microenvironment complexity and therapeutic implications at a glance (2020) · cites this paper as [9]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Liu, Y., Liang, X., Yin, X., Lv, J., Tang, K., Ma, J., Ji, T., Zhang, H., Dong, W., Jin, X., et al. (2017) · Nature Communications · doi:10.1038/ncomms15207 · Cited by 212 · cited 2×
“Blockade of IDO/AhR metabolic circuitry not only nullifies IFN-γ-mediated latency but also promotes amplified tumor cell growth arrest by IFN-γ-dependent killing of TRCs in vitro and in vivo [44,45].”
BackgroundRetractedJavaheri, T., Kazemi, Z., Pencik, J., Pham, H. T., Kauer, M., Noorizadeh, R., Sax, B., Nivarthi, H., Schlederer, M., Maurer, B., et al. (2016) · Cell Death & Disease · doi:10.1038/cddis.2016.268 · Cited by 18 · cited 1×
“cell cycle arrest, apoptosis and persistent BCL1 dormancy in mice [115].”
BackgroundSelf-citationRetractedHolmgren, L., O'Reilly, M. S., & Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0295-149 · Cited by 1,878 · cited 2×
“Notably, metastatic dormancy can be realized once the proliferation of tumor cell is well-balanced with an equal ratio of tumor cell apoptosis, indicating that anti-angiogenic treatment regulates metastatic outgrowth through increasing of cancer cell death [21].”
BackgroundThe Cancer Stem Cell Niche: How Essential Is the Niche in Regulating Stemness of Tumor Cells?
Plaks, V., Kong, N., & Werb, Z. (2015) · Cell Stem Cell · doi:10.1016/j.stem.2015.02.015 · Cited by 1,557 · cited 2×
“Notably, CSCs can adj t the expression of different surface markers which help them to colonize their desired target organs, in particular, the bone [129].”
BackgroundNeutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice
Albrengues, J., Shields, M. A., Ng, D., Park, C. G., Ambrico, A., Poindexter, M. E., Upadhyay, P., Uyeminami, D. L., Pommier, A., Küttner, V., et al. (2018) · Science · doi:10.1126/science.aao4227 · Cited by 1,476 · cited 2×
“Meanwhile, one study to recapitulate sustained inflammation in lungs as demonstrated in smoker individuals revealed that neutrophil extracellular traps (NETs) proteases (elastase and MMP9) produced during inflammation can degrade laminin which further induces proliferation of dormant cells through activating αvβ3 inte…”
BackgroundThe perivascular niche regulates breast tumour dormancy
Ghajar, C. M., Peinado, H., Mori, H., Matei, I. R., Evason, K. J., Brazier, H., Almeida, D., Koller, A., Hajjar, K. A., Stainier, D. Y. R., et al. (2013) · Nature Cell Biology · doi:10.1038/ncb2767 · Cited by 1,148 · cited 1×
“Studies on engineered organotypic microvascular niches established that while a Thrombospondin-1 secretion from endothelial cells induces maintained BCC dormancy, bioactive Periostin and TGF-β1 function as tumor-promoting factors in sprouting neovasculature which further sparks micrometastatic outgrowth [33].”
BackgroundKiSS-1, a Novel Human Malignant Melanoma Metastasis-Suppressor Gene
Lee, J.-H., Miele, M. E., Hicks, D. J., Phillips, K. K., Trent, J. M., Weissman, B. E., & Welch, D. R. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.23.1731 · Cited by 1,072
The quest to overcome resistance to EGFR-targeted therapies in cancer
Chong, C. R., & Jänne, P. A. (2013) · Nature Medicine · doi:10.1038/nm.3388 · Cited by 1,052 · cited 1×
“Meanwhile, EGFR signaling via activation of PI3K/AKT/mTOR and Ras/Raf/ERK axis is another contribution to tumor proliferation [124].”
BackgroundTumorigenic and Immunosuppressive Effects of Endoplasmic Reticulum Stress in Cancer
Cubillos-Ruiz, J. R., Bettigole, S. E., & Glimcher, L. H. (2017) · Cell · doi:10.1016/j.cell.2016.12.004 · Cited by 895
Bragado, P., Estrada, Y., Parikh, F., Krause, S., Capobianco, C., Farina, H. G., Schewe, D. M., & Aguirre-Ghiso, J. A. (2013) · Nature Cell Biology · doi:10.1038/ncb2861 · Cited by 503
Krall, J. A., Reinhardt, F., Mercury, O. A., Pattabiraman, D. R., Brooks, M. W., Dougan, M., Lambert, A. W., Bierie, B., Ploegh, H. L., Dougan, S. K., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan3464 · Cited by 442 · cited 1×
“To this end, it was reported that inflammation and wound healing process following surgery is enough to induce distant cancer outgrowth[52], especially when the tumor outgrowth was attenuated by the adaptive immune system [53].”
BackgroundThe BMP Inhibitor Coco Reactivates Breast Cancer Cells at Lung Metastatic Sites
Gao, H., Chakraborty, G., Lee-Lim, A. P., Mo, Q., Decker, M., Vonica, A., Shen, R., Brogi, E., Brivanlou, A. H., & Giancotti, F. G. (2012) · Cell · doi:10.1016/j.cell.2012.06.035 · Cited by 430
Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone
Kobayashi, A., Okuda, H., Xing, F., Pandey, P. R., Watabe, M., Hirota, S., Pai, S. K., Liu, W., Fukuda, K., Chambers, C., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20110840 · Cited by 427
Inhibition of Metastatic Outgrowth from Single Dormant Tumor Cells by Targeting the Cytoskeleton
Barkan, D., Kleinman, H., Simmons, J. L., Asmussen, H., Kamaraju, A. K., Hoenorhoff, M. J., Liu, Z.-Y., Costes, S. V., Cho, E. H., Lockett, S., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6849 · Cited by 425 · cited 1×
“Further, blockade of β1 integrin or MLCK favored dormancy state and MLCK inhibition significantly reduced metastatic expansion in vivo [56].”
BackgroundA model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype
Naumov, G. N., Bender, E., Zurakowski, D., Kang, S.-Y., Sampson, D., Flynn, E., Watnick, R. S., Straume, O., Akslen, L. A., Folkman, J., et al. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj068 · Cited by 423 · cited 3×
“As a foremost contributing factor to tumor dormancy is the incompetence of proliferating tumors to acquire the angiogenic potential to induce the f rmati of new blood vessels [97].”
BackgroundInfluentialCancer Stem Cell Quiescence and Plasticity as Major Challenges in Cancer Therapy
Chen, W., Dong, J., Haiech, J., Kilhoffer, M.-C., & Zeniou, M. (2016) · Stem Cells International · doi:10.1155/2016/1740936 · Cited by 402 · cited 3×
“Cumulative evidence suggests that CSCs are indeed metastasis-initiating cells, or metastatic cells acquire CSC-like phenotype upon infiltration into target organs [16,126].”
BackgroundMetastatic Growth from Dormant Cells Induced by a Col-I–Enriched Fibrotic Environment
Barkan, D., El Touny, L. H., Michalowski, A. M., Smith, J. A., Chu, I., Davis, A. S., Webster, J. D., Hoover, S., Simpson, R. M., Gauldie, J., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2356 · Cited by 394 · cited 1×
“Blockade of β1-integrin, MLCK, ERK, Src counteracted Col-I-mediated induction of this signaling cascade, cytoskeletal rearrangement, and proliferating state in the faithfully stimulated metastatic microenvironment in vivo [57].”
BackgroundBliss, S. A., Sinha, G., Sandiford, O. A., Williams, L. M., Engelberth, D. J., Guiro, K., Isenalumhe, L. L., Greco, S. J., Ayer, S., Bryan, M., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1092 · Cited by 383 · cited 1×
“Further, administration of MSC-loaded antagomiR-222/223 sensitized BC cells to carboplatin-based therapy and increased survival of the mouse as the model for studying miRNA-regulated breast cancer dormancy [84].”
BackgroundExtracellular matrix: A gatekeeper in the transition from dormancy to metastatic growth
Barkan, D., Green, J. E., & Chambers, A. F. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.02.027 · Cited by 377 · cited 1×
“Generally, the inability of cancer cells to appropriately adhere the ECM may potentiate their entry into a dormancy state [64].”
BackgroundTissue-resident memory CD8+ T cells promote melanoma–immune equilibrium in skin
Park, S. L., Buzzai, A., Rautela, J., Hor, J. L., Hochheiser, K., Effern, M., McBain, N., Wagner, T., Edwards, J., McConville, R., et al. (2019) · Nature · doi:10.1038/s41586-018-0812-9 · Cited by 375 · cited 1×
“Recently, CD8+ T cells are shown to play a key role in maintaining tumor dormancy, as tissue-resident memory CD8+ T cells (epidermal CD69+ CD103+ TRM cells) are implicated in the melanoma-immune equilibrium and control the active disease as demonstrated in skin-implanted melanoma cancer cells in mice model [107].”
BackgroundImmune-mediated dormancy: an equilibrium with cancer
Teng, M. W. L., Swann, J. B., Koebel, C. M., Schreiber, R. D., & Smyth, M. J. (2008) · Journal of Leukocyte Biology · doi:10.1189/jlb.1107774 · Cited by 359 · cited 1×
“Nonetheless, the perturbation of the equilibration in favor of immune escape will result in tumor outgrowth rather than the destruction of cancer cells, otherwise, immune surveillance could maintain angiogenic control and impede cancer cell growth (Figure 1) [105].”
BackgroundNR2F1 controls tumour cell dormancy via SOX9- and RARβ-driven quiescence programmes
Sosa, M. S., Parikh, F., Maia, A. G., Estrada, Y., Bosch, A., Bragado, P., Ekpin, E., George, A., Zheng, Y., Lam, H.-M., et al. (2015) · Nature Communications · doi:10.1038/ncomms7170 · Cited by 355
ATF6α-Rheb-mTOR signaling promotes survival of dormant tumor cells in vivo
Schewe, D. M., & Aguirre-Ghiso, J. A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0800939105 · Cited by 340
Fluegen, G., Avivar-Valderas, A., Wang, Y., Padgen, M. R., Williams, J. K., Nobre, A. R., Calvo, V., Cheung, J. F., Bravo-Cordero, J. J., Entenberg, D., et al. (2017) · Nature Cell Biology · doi:10.1038/ncb3465 · Cited by 336 · cited 1×
“In response to a stressor such as chemotherapy, radiation therapy, or O2/nutrient scarcity, stressed-tumor cells that survive apoptosis become dormant [3-6].”
BackgroundRanganathan, A. C., Zhang, L., Adam, A. P., & Aguirre-Ghiso, J. A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3092 · Cited by 331 · cited 1×
“Thus, p38 signaling via PERK activation and BiP up-regulation secures dormant human squamous carcinoma cells (HEp3) from stress insults, such as chemotherapy in vivo [90].”
BackgroundSeraj, M. J., Samant, R. S., Verderame, M. F., & Welch, D. R. (2000) · PubMed · Cited by 265
Johnson, R. W., Finger, E. C., Olcina, M. M., Vilalta, M., Aguilera, T., Miao, Y., Merkel, A. R., Johnson, J. R., Sterling, J. A., Wu, J. Y., et al. (2016) · Nature Cell Biology · doi:10.1038/ncb3408 · Cited by 262 · cited 1×
“Accordingly, inhibition of Zeb1, LIFR: STAT3 signaling [52] as well as blocking the actions of inflammatory cytokines such as tumor necrosis factor α (TNFα) and IL-1β cytokines could confer dormancy and thus eliminate cancer outgrowth [46].”
BackgroundZhang, X., Fryknäs, M., Hernlund, E., Fayad, W., De Milito, A., Olofsson, M. H., Gogvadze, V., Dang, L., Påhlman, S., Schughart, L. A. K., et al. (2014) · Nature Communications · doi:10.1038/ncomms4295 · Cited by 253 · cited 1×
“The anti-tumor potential is correlated with dampened mitochondrial respiration, culminating in bioenergetic catastrophe and tumor cell apoptosis [58].”
BackgroundTargeting the perivascular niche sensitizes disseminated tumour cells to chemotherapy
Carlson, P., Dasgupta, A., Grzelak, C. A., Kim, J., Barrett, A., Coleman, I. M., Shor, R. E., Goddard, E. T., Dai, J., Schweitzer, E. M., et al. (2019) · Nature Cell Biology · doi:10.1038/s41556-018-0267-0 · Cited by 251 · cited 1×
“Recently, targeting the perivascular niche with integrin inhibitors are exploited for chemosensitization of breast cancer cells and the prevention of bone metastasis in mice [123].”
BackgroundGao, H., Chakraborty, G., Zhang, Z., Akalay, I., Gadiya, M., Gao, Y., Sinha, S., Hu, J., Jiang, C., Akram, M., et al. (2016) · Cell · doi:10.1016/j.cell.2016.06.009 · Cited by 246
Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype
Almog, N., Ma, L., Raychowdhury, R., Schwager, C., Erber, R., Short, S., Hlatky, L., Vajkoczy, P., Huber, P. E., Folkman, J., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2590 · Cited by 240 · cited 2×
“The transformation of quiescent tumors to highly proliferating tumors was also associated with the activation and regulation of molecular cues connected to tumor dormancy [34].”
BackgroundPrice, T. T., Burness, M. L., Sivan, A., Warner, M. J., Cheng, R., Lee, C. H., Olivere, L., Comatas, K., Magnani, J., Kim Lyerly, H., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad4059 · Cited by 239 · cited 1×
“Thus, a combined therapy involving CXCR4/E-selectin inhibition will push cells out of their protective niches and aid trapping of the cells in the vasculature, where they could be destroyed with chemotherapy, thus provide an opportunity to control recurrent disease [73].”
BackgroundInteraction of KAI1 on tumor cells with DARC on vascular endothelium leads to metastasis suppression
Bandyopadhyay, S., Zhan, R., Chaudhuri, A., Watabe, M., Pai, S. K., Hirota, S., Hosobe, S., Tsukada, T., Miura, K., Takano, Y., et al. (2006) · Nature Medicine · doi:10.1038/nm1444 · Cited by 235
Sosa, M. S., Avivar-Valderas, A., Bragado, P., Wen, H.-C., & Aguirre-Ghiso, J. A. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2574 · Cited by 233
Microfluidics: A New Tool for Modeling Cancer–Immune Interactions
Boussommier-Calleja, A., Li, R., Chen, M. B., Wong, S. C., & Kamm, R. D. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2015.12.003 · Cited by 224
Microfluidics and Circulating Tumor Cells
Dong, Y., Skelley, A. M., Merdek, K. D., Sprott, K. M., Jiang, C., Pierceall, W. E., Lin, J., Stocum, M., Carney, W. P., & Smirnov, D. A. (2013) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2012.09.004 · Cited by 219
Cancer Dormancy: A Model of Early Dissemination and Late Cancer Recurrence
Páez, D., Labonte, M. J., Bohanes, P., Zhang, W., Benhanim, L., Ning, Y., Wakatsuki, T., Loupakis, F., & Lenz, H.-J. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2186 · Cited by 215
Wnt5a induces and maintains prostate cancer cells dormancy in bone
Ren, D., Dai, Y., Yang, Q., Zhang, X., Guo, W., Ye, L., Huang, S., Chen, X., Lai, Y., Du, H., et al. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20180661 · Cited by 204
Modulating tumor hypoxia by nanomedicine for effective cancer therapy
Jahanban‐Esfahlan, R., de la Guardia, M., Ahmadi, D., & Yousefi, B. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.25859 · Cited by 201 · cited 1×
“They undergo drastic changes in cellular physiology to shape the surrounding microenvironment to best fit their requirements [1].”
BackgroundSelf-citationCancer dormancy: Opportunities for new therapeutic approaches
Uhr, J. W., Scheuermann, R. H., Street, N. E., & Vitetta, E. S. (1997) · Nature Medicine · doi:10.1038/nm0597-505 · Cited by 188 · cited 1×
“In tumor mass dormancy a stagnation of total tumor growth due to the equilibrium of proliferation and apoptosis is governed by an angiogenic switch or immune escape (two prevailing mechanisms) that eventually shifts the balance in favor of cancer progression [8].”
BackgroundLACTB is a tumour suppressor that modulates lipid metabolism and cell state
Keckesova, Z., Donaher, J. L., De Cock, J., Freinkman, E., Lingrell, S., Bachovchin, D. A., Bierie, B., Tischler, V., Noske, A., Okondo, M. C., et al. (2017) · Nature · doi:10.1038/nature21408 · Cited by 187 · cited 1×
“Conversely, LACTB silencing in non-tumorigenic breast cell lines cooperated with oncogenic drivers (HRASG12V and MYCT58A) supporting tumor formation in xenotransplants [61,62].”
BackgroundYu-Lee, L.-Y., Yu, G., Lee, Y.-C., Lin, S.-C., Pan, J., Pan, T., Yu, K.-J., Liu, B., Creighton, C. J., Rodriguez-Canales, J., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-1051 · Cited by 172
Axl is required for TGF-β2-induced dormancy of prostate cancer cells in the bone marrow
Yumoto, K., Eber, M. R., Wang, J., Cackowski, F. C., Decker, A. M., Lee, E., Nobre, A. R., Aguirre-Ghiso, J. A., Jung, Y., & Taichman, R. S. (2016) · Scientific Reports · doi:10.1038/srep36520 · Cited by 170
Adam, A. P., George, A., Schewe, D., Bragado, P., Iglesias, B. V., Ranganathan, A. C., Kourtidis, A., Conklin, D. S., & Aguirre-Ghiso, J. A. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3820 · Cited by 168 · cited 2×
“Stress-induced activation of p38 signaling is one of the critical pathways related to tumor dormancy, which regulates a transcriptional network of 46 core genes that includes 16 transcription factors (TFs) [91].”
BackgroundMetabolic shifts in residual breast cancer drive tumor recurrence
Havas, K. M., Milchevskaya, V., Radic, K., Alladin, A., Kafkia, E., Garcia, M., Stolte, J., Klaus, B., Rotmensz, N., Gibson, T. J., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci89914 · Cited by 168 · cited 4×
“That, blockade of either transportation of fatty acid into mitochondria or synthesis of cellular fatty acid lessens DNA damages and cellular reactive oxygen species (ROS) levels, connecting these hallmarks to lipid metabolism.”
BackgroundInfluentialMicrofluidic technologies for circulating tumor cell isolation
Cho, H., Kim, J., Song, H., Sohn, K. Y., Jeon, M., & Han, K.-H. (2018) · The Analyst · doi:10.1039/c7an01979c · Cited by 167
Cancer cells enter dormancy after cannibalizing mesenchymal stem/stromal cells (MSCs)
Bartosh, T. J., Ullah, M., Zeitouni, S., Beaver, J., & Prockop, D. J. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1612290113 · Cited by 164
Inflammation Triggers Zeb1-Dependent Escape from Tumor Latency
De Cock, J. M., Shibue, T., Dongre, A., Keckesova, Z., Reinhardt, F., & Weinberg, R. A. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0608 · Cited by 155 · cited 1×
“Likewise, Zeb1-orchestrated stimulation of EMT program by itself is sufficient to provoke metastatic spread by triggering stable entry of tumor cells into a state of metastasis-initiating cells [54].”
BackgroundA review of microfluidic approaches for investigating cancer extravasation during metastasis
Ma, Y.-H. V., Middleton, K., You, L., & Sun, Y. (2018) · Microsystems & Nanoengineering · doi:10.1038/micronano.2017.104 · Cited by 154
Notch promotes recurrence of dormant tumor cells following HER2/neu-targeted therapy
Abravanel, D. L., Belka, G. K., Pan, T.-C., Pant, D. K., Collins, M. A., Sterner, C. J., & Chodosh, L. A. (2015) · Journal of Clinical Investigation · doi:10.1172/jci74883 · Cited by 148 · cited 1×
“(VEGF(121) VEGF(165) overexpression Angiogenic dormancy The level and VEGF isoforms determine a fate of aggressive tumor growth vs.”
BackgroundSuppression of heat shock protein 27 induces long-term dormancy in human breast cancer
Straume, O., Shimamura, T., Lampa, M., Carretero, J., Oyan, A. M., Jia, D., Borgman, C. L., Soucheray, M., Downing, S. R., Short, S. M., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1017909109 · Cited by 148
Combined SFK/MEK inhibition prevents metastatic outgrowth of dormant tumor cells
El Touny, L. H., Vieira, A., Mendoza, A., Khanna, C., Hoenerhoff, M. J., & Green, J. E. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70259 · Cited by 144 · cited 1×
“These results were obtained using the fibrosis-induced dormant-to-proliferative switch in vitro, in vivo and also ex vivo lung metastasis assay [59].”
MethodChronic Inflammation and Breast Cancer Recurrence
Cole, S. W. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.21.9782 · Cited by 141 · cited 1×
“Also, the paradox role of pro- and anti-proliferative action of the immune system is shown in tumor evolution [22].”
BackgroundMSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer
Gawrzak, S., Rinaldi, L., Gregorio, S., Arenas, E. J., Salvador, F., Urosevic, J., Figueras-Puig, C., Rojo, F., Barrantes, I. D. B., Cejalvo, J. M., et al. (2018) · Nature Cell Biology · doi:10.1038/s41556-017-0021-z · Cited by 141
Type I interferon/IRF7 axis instigates chemotherapy-induced immunological dormancy in breast cancer
Lan, Q., Peyvandi, S., Duffey, N., Huang, Y.-T., Barras, D., Held, W., Richard, F., Delorenzi, M., Sotiriou, C. P., Desmedt, C., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0624-2 · Cited by 141 · cited 1×
“With regards to the role of other interferons, a recent study demonstrated the role of IFN-β-induced immunological dormancy reflected in sustained activation of the IRF7/IFN-β/IFNAR axis in chemo-resistant (high dose doxorubicin and methotrexate) ER-negative 4T1 breast cancer cells in vitro and in vivo [110].”
BackgroundCancer stem cells-emanated therapy resistance: Implications for liposomal drug delivery systems
Dianat-Moghadam, H., Heidarifard, M., Jahanban-Esfahlan, R., Panahi, Y., Hamishehkar, H., Pouremamali, F., Rahbarghazi, R., & Nouri, M. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.08.043 · Cited by 140 · cited 2×
“Cumulative evidence suggests that CSCs are indeed metastasis-initiating cells, or metastatic cells acquire CSC-like phenotype upon infiltration into target organs [16,126].”
BackgroundSelf-citationA Novel Model of Dormancy for Bone Metastatic Breast Cancer Cells
Marlow, R., Honeth, G., Lombardi, S., Cariati, M., Hessey, S., Pipili, A., Mariotti, V., Buchupalli, B., Foster, K., Bonnet, D. A., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0991 · Cited by 139 · cited 1×
“While the critical role of numerous microRNAs in tumorigenesis is well documented [133], the implication of dormancy miRNAs (Dmirs) is just recently illuminated [134].”
BackgroundChapter 3 Tumor Dormancy and Metastasis
Hedley, B. D., & Chambers, A. F. (2009) · Advances in cancer research · doi:10.1016/s0065-230x(09)02003-x · Cited by 132 · cited 1×
“The implication of tumor cell dormancy is very well established in the development of multidrug resistance (MDR), minimum residual disease (MRD), tumor outgrowth, and metastatic relapse [13-15], leading to cancer treatment failure.”
BackgroundSaudemont, A., Jouy, N., Hetuin, D., & Quesnel, B. (2005) · Blood · doi:10.1182/blood-2004-09-3458 · Cited by 132 · cited 2×
“Paradoxically, while expression of B7-H1 on the surface of tumor cells impairs dormant cancer cell-killing potential of T-cells, expression of same surface receptors by natural killer (NK) cells (induced by CXCL10) can activate them to prompt a cytotoxic T lymphocyte (CTL) response resulting in destruction of otherwis…”
BackgroundGAS6 Receptor Status Is Associated with Dormancy and Bone Metastatic Tumor Formation
Taichman, R. S., Patel, L. R., Bedenis, R., Wang, J., Weidner, S., Schumann, T., Yumoto, K., Berry, J. E., Shiozawa, Y., & Pienta, K. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061873 · Cited by 132
The roles of Wnt/β‐catenin pathway in tissue development and regenerative medicine
Majidinia, M., Aghazadeh, J., Jahanban‐Esfahlani, R., & Yousefi, B. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26265 · Cited by 132
Self-citationTumor dormancy due to failure of angiogenesis: role of the microenvironment
Naumov, G. N., Folkman, J., & Straume, O. (2008) · Clinical & Experimental Metastasis · doi:10.1007/s10585-008-9176-0 · Cited by 131 · cited 1×
“4 of which is under the control of intricate biological processes comprising the cancer cells, bone marrow-derived endothelial precursors, and tumor associated-stromal microenvironment [27].”
BackgroundIFN-γ orchestrates tumor elimination, tumor dormancy, tumor escape, and progression
Aqbi, H. F., Wallace, M., Sappal, S., Payne, K. K., & Manjili, M. H. (2018) · Journal of Leukocyte Biology · doi:10.1002/jlb.5mir0917-351r · Cited by 126
Self-citationHMGA1: A Master Regulator of Tumor Progression in Triple-Negative Breast Cancer Cells
Shah, S. N., Cope, L., Poh, W., Belton, A., Roy, S., Talbot, C. C., Sukumar, S., Huso, D. L., & Resar, L. M. S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063419 · Cited by 123
Tumor Dormancy and Relapse: From a Natural Byproduct of Evolution to a Disease State
Manjili, M. H. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0068 · Cited by 115 · cited 1×
“Increasing inflammation promotes tumor recurrence, thus interventions that inhibit inflammatory signaling could inhibit tumor recurrence[50,51].”
BackgroundSelf-citationNR2F1 stratifies dormant disseminated tumor cells in breast cancer patients
Borgen, E., Rypdal, M. C., Sosa, M. S., Renolen, A., Schlichting, E., Lønning, P. E., Synnestvedt, M., Aguirre-Ghiso, J. A., & Naume, B. (2018) · Breast Cancer Research · doi:10.1186/s13058-018-1049-0 · Cited by 114 · cited 1×
“In this respect, epigenetic upregulation of orphan nuclear receptor NR2F1 is detected in DTCs from the breast [131], and prostate cancer patients harboring lifelong dormant disease and in experimental latency models of head and neck squamous cell carcinoma (HNSCC).”
BackgroundTBK1 Regulates Prostate Cancer Dormancy through mTOR Inhibition
Kim, J. K., Jung, Y., Wang, J., Joseph, J., Mishra, A., Hill, E. E., Krebsbach, P. H., Pienta, K. J., Shiozawa, Y., & Taichman, R. S. (2013) · Neoplasia · doi:10.1593/neo.13402 · Cited by 113
Cancer cell dormancy: mechanisms and implications of cancer recurrence and metastasis
Gao, X., Zhang, M., Tang, Y., & Liang, X.-H. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s140854 · Cited by 113
Prolonged dormancy of human liposarcoma is associated with impaired tumor angiogenesis
Almog, N., Henke, V., Flores, L., Hlatky, L., Kung, A. L., Wright, R. D., Berger, R., Hutchinson, L., Naumov, G. N., Bender, E., et al. (2006) · The FASEB Journal · doi:10.1096/fj.05-3946fje · Cited by 112 · cited 2×
“This type of tumor with no angiogenic activity produce moderately high amount of the anti-angiogenesis agents TIMP-1 and thrombospondin-1, proposing that the nonangiogenic, microscopic, dormant stage of melanoma might be susceptible to anti-angiogenic treatment years prior to manifestation of malignant disease, or mac…”
BackgroundRanganathan, A. C., Adam, A. P., Zhang, L., & Aguirre-Ghiso, J. A. (2006) · Cancer Biology & Therapy · doi:10.4161/cbt.5.7.2968 · Cited by 110 · cited 1×
“p38 MAPK signaling coordinates the induction of growth arrest and drug-resistance in different models of cancer cell dormancy [136].”
BackgroundSharma, S., Xing, F., Liu, Y., Wu, K., Said, N., Pochampally, R., Shiozawa, Y., Lin, H.-K., Balaji, K. C., & Watabe, K. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.737379 · Cited by 109
Walker, N. D., Elias, M., Guiro, K., Bhatia, R., Greco, S. J., Bryan, M., Gergues, M., Sandiford, O. A., Ponzio, N. M., Leibovich, S. J., et al. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-1304-z · Cited by 107
Opposing Roles of Mitogenic and Stress Signaling Pathways in the Induction of Cancer Dormancy
Ranganathan, A. C., Adam, A. P., & Aguirre‐Ghiso, J. A. (2006) · Cell Cycle · doi:10.4161/cc.5.16.3109 · Cited by 103
To wake up cancer stem cells, or to let them sleep, that is the question
Takeishi, S., & Nakayama, K. I. (2016) · Cancer Science · doi:10.1111/cas.12958 · Cited by 102 · cited 3×
“Tumor cell entrance into and out o dormancy is regul te by contextual cues and intrinsic programs, like those that control the self-renewal ability of mature stem cells [125].”
BackgroundInfluentialYu, J., Rak, J. W., Klement, G. L., & Kerbel, R. S. (2002) · PubMed · Cited by 99
Griend, D. J. V., Kocherginsky, M., Hickson, J. A., Stadler, W. M., Lin, A., & Rinker-Schaeffer, C. W. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2382 · Cited by 97
Surgery Triggers Outgrowth of Latent Distant Disease in Breast Cancer: An Inconvenient Truth?
Retsky, M. W., Demicheli, R., Hrushesky, W. J. M., Baum, M., & Gukas, I. D. (2010) · Cancers · doi:10.3390/cancers2020305 · Cited by 96
Tumor dormancy of primary and secondary cancers
Udagawa, T. (2008) · Apmis · doi:10.1111/j.1600-0463.2008.01077.x · Cited by 94 · cited 1×
“After cessation of the therapy, the dormant cells may repopulate, resulting in tumor recurrence and development of chemotherapyresistant cancer cells [2,3].”
BackgroundTGF-β Family Signaling Pathways in Cellular Dormancy
Prunier, C., Baker, D. A., ten Dijke, P., & Ritsma, L. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.10.010 · Cited by 94 · cited 1×
“A detailed role of TGF-β related cellular dormancy is recently reviewed in [102].”
BackgroundWaking up dormant tumor suppressor genes with zinc fingers, TALEs and the CRISPR/dCas9 system
Garcia-Bloj, B., Moses, C., Sgro, A., Plani-Lam, J., Arooj, M., Duffy, C., Thiruvengadam, S., Sorolla, A., Rashwan, R., Mancera, R. L., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11142 · Cited by 91 · cited 1×
“These models were somewhat successful in recapitulating dormancy mechanism of tumors, as they lead to the discovery of cellular dormancy factors/mechanisms including extracellular matrix (ECM) [10], metabolic [11,12], epigenetic [13,14], stemness [15,16], non-coding RNAs [17], and p38 stress-induced signaling pathway…”
BackgroundTumor dormancy and immunoescape
QUESNEL, B. (2008) · APMIS · doi:10.1111/j.1600-0463.2008.01163.x · Cited by 90 · cited 1×
“Cancer cells are encircled by stromal cells, including macrophages, fibroblasts, mast cells, neutrophils, and lymphocytes, which communicate through an intricate system of intercellular signaling pathways, mediated by cytokines, adhesion molecules, and the receptor-ligand network [42].”
BackgroundMetastases in Immune-Mediated Dormancy: A New Opportunity for Targeting Cancer
Romero, I., Garrido, F., & Garcia-Lora, A. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-2406 · Cited by 86 · cited 1×
“In this view, treatment modalities that induce or amplify the CTL immune response or abrogate CTL immunosuppression mediated by cancer cells might be beneficial to confine or eradicate metastatic cells [41,42].”
BackgroundTiram, G., Segal, E., Krivitsky, A., Shreberk-Hassidim, R., Ferber, S., Ofek, P., Udagawa, T., Edry, L., Shomron, N., Roniger, M., et al. (2016) · ACS Nano · doi:10.1021/acsnano.5b06189 · Cited by 86 · cited 1×
“Furthermore, therapy with dPG-NH2 containing each of these microRNAs considerably extended the latency state of fast-growing osteosarcomas in mice [85].”
BackgroundMer Tyrosine Kinase Regulates Disseminated Prostate Cancer Cellular Dormancy
Cackowski, F. C., Eber, M. R., Rhee, J., Decker, A. M., Yumoto, K., Berry, J. E., Lee, E., Shiozawa, Y., Jung, Y., Aguirre‐Ghiso, J. A., et al. (2016) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25768 · Cited by 84
Induction of dormancy in hypoxic human papillomavirus-positive cancer cells
Hoppe‐Seyler, K., Bossler, F., Lohrey, C., Bulkescher, J., Rösl, F., Jansen, L., Mayer, A., Vaupel, P. W., Dürst, M., & Hoppe‐Seyler, F. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1615758114 · Cited by 84
Combination of nanotechnology with vascular targeting agents for effective cancer therapy
Jahanban‐Esfahlan, R., Seidi, K., Banimohamad‐Shotorbani, B., Jahanban‐Esfahlan, A., & Yousefi, B. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26051 · Cited by 84 · cited 3×
“This point of cancer progression is recognized as an angiogenic switch, the induction of which is under the control of intricate biological processes comprising the cancer cells, BM-derived endothelial precursors, and tumor associated-stromal micro nvironment [98,99].”
BackgroundInfluentialSelf-citationT Lymphocytes Restrain Spontaneous Metastases in Permanent Dormancy
Romero, I., Garrido, C., Algarra, I., Collado, A., Garrido, F., & Garcia-Lora, A. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2084 · Cited by 79 · cited 1×
“Of note, immunodepletion of T lymphocytes or asialo GM1-positive cells results in relieving the restraint dormant cells into disseminated MHC-1 positive metastatic cells in mice lungs [106].”
BackgroundDormancy and growth of metastatic breast cancer cells in a bone-like microenvironment
Sosnoski, D. M., Norgard, R. J., Grove, C. D., Foster, S. J., & Mastro, A. M. (2015) · Clinical & Experimental Metastasis · doi:10.1007/s10585-015-9710-9 · Cited by 79
Engineered In Vitro Models of Tumor Dormancy and Reactivation
Pradhan, S., Sperduto, J. L., Farino, C. J., & Slater, J. H. (2018) · Journal of Biological Engineering · doi:10.1186/s13036-018-0120-9 · Cited by 78
The epigenetic/noncoding origin of tumor dormancy
Crea, F., Saidy, N. R. N., Collins, C. C., & Wang, Y. Z. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.02.005 · Cited by 77 · cited 1×
“These models were somewhat successful in recapitulating dormancy mechanism of tumors, as they lead to the discovery of cellular dormancy factors/mechanisms including extracellular matrix (ECM) [10], metabolic [11,12], epigenetic [13,14], stemness [15,16], non-coding RNAs [17], and p38 stress-induced signaling pathway…”
BackgroundAutophagy-deficient breast cancer shows early tumor recurrence and escape from dormancy
Aqbi, H. F., Tyutyunyk-Massey, L., Keim, R. C., Butler, S. E., Thekkudan, T., Joshi, S., Smith, T. M., Bandyopadhyay, D., Idowu, M. O., Bear, H. D., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25197 · Cited by 76 · cited 2×
“That, the lack of autophagy, which is exploited as an important compensatory mechanism by tumor cells to provide their energy requirements, associates with an early breast cancer recurrence and escape from dormancy as demonstrated in neu-overexpressing mouse mammary carcinoma (MMC) [120].”
BackgroundSelf-citationAutocrine IGF1 Signaling Mediates Pancreatic Tumor Cell Dormancy in the Absence of Oncogenic Drivers
Rajbhandari, N., Lin, W.-C., Wehde, B. L., Triplett, A. A., & Wagner, K.-U. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.02.013 · Cited by 68
Cellular Adhesion Promotes Prostate Cancer Cells Escape from Dormancy
Ruppender, N. S., Larson, S. R., Lakely, B., Kollath, L. A., Brown, L. G., Coleman, I. M., COLEMAN, R. T., Nguyen, H. M., Nelson, P. S., Corey, E., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0130565 · Cited by 67
Asai, T., Liu, Y., Di Giandomenico, S., Bae, N., Ndiaye-Lobry, D., Deblasio, A., Menendez, S., Antipin, Y., Reva, B., Wevrick, R., et al. (2012) · Blood · doi:10.1182/blood-2011-11-393983 · Cited by 67
Consensus Micro RNAs Governing the Switch of Dormant Tumors to the Fast-Growing Angiogenic Phenotype
Almog, N., Ma, L., Schwager, C., Brinkmann, B. G., Beheshti, A., Vajkoczy, P., Folkman, J., Hlatky, L., & Abdollahi, A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044001 · Cited by 67 · cited 4×
“[95] Inducer of stress-induced dormancy MKK7 activ tes MAPK and JNK. [96] Abbreviations: N-myc downstream-regulated gene 1 (NDRG1); BMP receptor 2 (BMPR2); indolamine 2,3-dioxygenase 1 (IDO1)-kynurenine (Kyn)-aryl hydrocarbon receptor (AhR) (IDO1/AhR); bone morphogenetic protein 7 (BMP7); N-myc downstream-regulated ge…”
BackgroundInfluentialRussell, R., Pedersen, A., Kantor, J. D., Geisinger, K. R., Long, R., Zbieranski, N., Townsend, A., Shelton, B. J., Brünner, N., & Kute, T. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.566 · Cited by 61
Mechanism of ECM-induced dormancy and chemoresistance in A549 human lung carcinoma cells
Keeratichamroen, S., Lirdprapamongkol, K., & Svasti, J. (2018) · Oncology Reports · doi:10.3892/or.2018.6258 · Cited by 61 · cited 1×
“Inhibition of one of the components of fibronectin/uPAR/integrin/ERK/MLCK signaling axis as well as suppressing PI3K/Akt pathway is sufficient to prevent/treat metastatic tumor outgrowth, meanwhile promotes dormancy state through favoring the p38 MAPK signaling [122].”
BackgroundTranscriptional changes induced by the tumor dormancy-associated microRNA-190
Almog, N., Briggs, C. E., Beheshti, A., Ma, L., Wilkie, K. P., Rietman, E. A., & Hlatky, L. (2013) · Transcription · doi:10.4161/trns.25558 · Cited by 58 · cited 7×
“Introduction of these miRNAs by dPG-NH2 polyplexes into MG-63 and Saos-2 cells dampened expression levels of their target genes, including hypoxia-inducible factor 1α (HIF1α), MET proto-oncogene, and moesin, vital to tumor migration and angiogenesis process.”
BackgroundInfluentialClark, A. M., Kumar, M. P., Wheeler, S. E., Young, C. L., Venkataramanan, R., Stolz, D. B., Griffith, L. G., Lauffenburger, D. A., & Wells, A. (2018) · Molecular & Cellular Proteomics · doi:10.1074/mcp.ra117.000370 · Cited by 56 · cited 1×
“Accordingly, current in vitro, in vivo and ex vivo (organs-on-a-chip) experimental models of cancer dormancy can mimic cellular and tumor mass dormancy (angiogenic and immunologic dormancy), each reflecting distinct growth kinetics [9].”
BackgroundSaudemont, A., Hamrouni, A., Marchetti, P., 刘继中, Jouy, N., Hétuin, D., Colucci, F., & Quesnel, B. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1627 · Cited by 55 · cited 2×
“IL-3) and simultaneous inactivation of SOCS1, the expression of which negatively controls JAK/STAT signaling [47].”
BackgroundMethodCross-regulation between Notch signaling pathway and miRNA machinery in cancer
Majidinia, M., Darband, S. G., Kaviani, M., Nabavi, S. M., Jahanban‐Esfahlan, R., & Yousefi, B. (2018) · DNA repair · doi:10.1016/j.dnarep.2018.04.002 · Cited by 54 · cited 1×
“While the critical role of numerous microRNAs in tumorigenesis is well documented [133], the implication of dormancy miRNAs (Dmirs) is just recently illuminated [134].”
BackgroundSelf-citationJiang, J., Zheng, M., Zhang, M., Yang, X., Li, L., Wang, S.-S., Wu, J.-S., Yu, X.-H., Wu, J.-B., Pang, X., et al. (2019) · Neoplasia · doi:10.1016/j.neo.2018.12.001 · Cited by 54
Nabavi, N., Saidy, N. R. N., Venalainen, E., Haegert, A. M., Parolia, A., Xue, H., Wang, Y., Wu, R. C., Dong, X., Collins, C. C., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-03731-8 · Cited by 53
Cancer Stem Cells, Bone and Tumor Microenvironment: Key Players in Bone Metastases
Roato, I., & Ferracini, R. (2018) · Cancers · doi:10.3390/cancers10020056 · Cited by 52 · cited 6×
“Moreover, the CXCR4/SDF-1 axis not only derives EMT for bone metastasis, but it also promotes breast cancer cell stemness, plasticity and maintenance of CSC-like properties in vivo [68].”
BackgroundInfluentialALLGAYER, H., & AGUIRRE‐GHISO, J. A. (2008) · APMIS · doi:10.1111/j.1600-0463.2008.00997.x · Cited by 50 · cited 1×
“2, inhibition of one of the components of Fibronectin/uPAR/Integrin/ERK/MLCK signaling axis as well as suppressing PI3K/Akt pathway is enough to prevent/treat metastatic tumor growth, meanwhile promoting dormancy state through favoring the p38 MAPK signaling [65,66].”
BackgroundThrombospondin-1-Mediated Metastasis Suppression by the Primary Tumor in Human Melanoma Xenografts
Rofstad, E. K., & Graff, B. A. (2001) · Journal of Investigative Dermatology · doi:10.1046/j.0022-202x.2001.01552.x · Cited by 49 · cited 1×
“In contrast to wild-type tumors with no thrombospondin-1 expression, a tumor-suppressive index was demonstrated only in mice bearing D-12, U-25, or thrombospondin-1 overexpressing R-18 tumors, as validated by melanoma angiogenesis, lung colonization, and spontaneous pulmonary metastasis [32].”
BackgroundSelli, Ç., Turnbull, A., Pearce, D., Li, A., Fernando, A., Wills, J. C., Renshaw, L., Thomas, J. S. J., Dixon, J. M., & Sims, A. H. (2019) · Breast Cancer Research · doi:10.1186/s13058-018-1089-5 · Cited by 49 · cited 1×
“Acquired resistance to estrogen depletion therapy with aromatase inhibitors was attributed to the dormancy highlighted with a global loss of DNA methylation under extended treatment [132].”
BackgroundA chromatin-independent role of Polycomb-like 1 to stabilize p53 and promote cellular quiescence
Brien, G. L., Healy, E., Jerman, E., Conway, E., Fadda, E., O’Donovan, D., Krivtsov, A. V., Rice, A. M., Kearney, C. J., Flaus, A., et al. (2015) · Genes & Development · doi:10.1101/gad.267930.115 · Cited by 45 · cited 1×
“Of note, PCL1 confers a PRC2 function which acts independent of chromatin, possessing anti-proliferating effect and induce cellular dormancy through binding to and stabilizing p53 [81].”
BackgroundGlobal Dormancy of Metastases Due to Systemic Inhibition of Angiogenesis
Benzekry, S., Gandolfi, A., & Hahnfeldt, P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0084249 · Cited by 39 · cited 3×
“Concerning the role of the a i genic switc in cancer dormancy, two therapeutic proaches follow: in the first approach, long-term dormancy can be induced using anti-angioge ic therapy as validated in different angiogenic models of dormancy in vivo [100].”
BackgroundInfluentialBioengineered models to study tumor dormancy
Rao, S. S., Kondapaneni, R. V., & Narkhede, A. A. (2019) · Journal of Biological Engineering · doi:10.1186/s13036-018-0137-0 · Cited by 39
Bayko, L., Rak, J. W., Man, S., Bicknell, R., Ferrara, N., & Kerbel, R. S. (1998) · Angiogenesis · doi:10.1023/a:1009275307663 · Cited by 37 · cited 1×
“These effects were largely counteracted by neutralizing VEGF activity in mice [33].”
BackgroundBarrios, J., & Wieder, R. (2009) · Cancer Microenvironment · doi:10.1007/s12307-009-0019-6 · Cited by 36
Watson, K. L. M., Jones, R. A., Bruce, A., & Moorehead, R. A. (2018) · Experimental Cell Research · doi:10.1016/j.yexcr.2018.04.024 · Cited by 34 · cited 1×
“Also, a recent study showed that metastatic outgrowth of the claudin-low mammary tumor cell line, RJ423 can be avoided by re-expression of the miR-200b/200a/429 cluster which promotes epithelial phenotype and induces tumor dormancy [87].”
BackgroundMao, W., Peters, H. L., Sutton, M. N., Orozco, A. F., Pang, L., Yang, H., Lü, Z., & Bast, R. C. (2019) · Cancer · doi:10.1002/cncr.31935 · Cited by 34
Protracted dormancy of pre-leukemic stem cells
Ford, A. M., Mansur, M. B., Furness, C. L., van Delft, F. W., Okamura, J., Suzuki, T., Kobayashi, H., Kaneko, Y., & Greaves, M. F. (2015) · Leukemia · doi:10.1038/leu.2015.132 · Cited by 32 · cited 2×
“Adopting a dormant state, CSCs not only can evade therapeutic killing, but the likely reversibility of this situation also poses the real threat, which can potentiate deadly relapse or recurrence decades lat r [128].”
BackgroundLotan, T. L., Hickson, J. A., Souris, J. S., Huo, D., Taylor, J., Li, T., Otto, K. B., Yamada, S. D., Macleod, K. F., & Rinker-Schaeffer, C. W. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-1568 · Cited by 32
Low Levels of Sox2 are required for Melanoma Tumor-Repopulating Cell Dormancy
Jia, Q., Yang, F., Huang, W., Zhang, Y., Bao, B., Li, K., Wei, F., Zhang, C., & Jia, H. (2019) · Theranostics · doi:10.7150/thno.29698 · Cited by 30
Ambs, S., Dennis, S., Fairman, J., Wright, M., & Papkoff, J. S. (1999) · PubMed · Cited by 29
Role of Tregs in Cancer Dormancy or Recurrence
Manjili, M. H., & Butler, S. E. (2016) · Immunological Investigations · doi:10.1080/08820139.2016.1194428 · Cited by 29 · cited 1×
“Meanwhile, an association of human Tregs, neutrophils and inflammatory mediators such as interferon-gamma (IFNγ) are rather context-dependent [109].”
BackgroundSelf-citationLoss of MED12 Induces Tumor Dormancy in Human Epithelial Ovarian Cancer via Downregulation of EGFR
Luo, X.-L., Deng, C., Su, X., Wang, F., Chen, Z., Wu, X.-P., Liang, S.-B., Liu, J., & Fu, L. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0134 · Cited by 29
Luo, J., Feng, X., Luo, C., Wang, Y., Li, D., Shu, Y., Wang, S., Qin, J., Li, Y., Zou, J.-M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9709 · Cited by 27
Gregoire, J.-M., Fleury, L., Salazar-Cardozo, C., Alby, F., Masson, V., Arimondo, P. B., & Ausseil, F. (2016) · BMC Cancer · doi:10.1186/s12885-016-2683-5 · Cited by 25 · cited 1×
“Identifying genes that encode these reversible alterations is an appealing therapeutic plan to combat metastatic disease by inducing differentiation of the mesenchymal cell into an epithelial phenotype [80].”
BackgroundExperimental models of bone metastasis: Opportunities for the study of cancer dormancy
Chong, M. S. K. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.12.007 · Cited by 24 · cited 1×
“Generally, cancer dormancy can be categorized as cellular dormancy or tumor mass dormancy [7].”
BackgroundYK-4-279 effectively antagonizes EWS-FLI1 induced leukemia in a transgenic mouse model
Minas, T. Z., Han, J., Javaheri, T., Hong, S.-H., Schlederer, M., Saygideğer-Kont, Y., Çelik, H., Mueller, K. M., Temel, I., Özdemirli, M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5520 · Cited by 23 · cited 1×
“, IL-3) and simultaneous inactivation of SOCS1, the expression of which negatively controls JAK/STAT signaling [114].”
BackgroundSelf-citationMaroni, P., Bendinelli, P., Matteucci, E., & Desiderio, M. A. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0499-8 · Cited by 21
Dudley, M. E., Sundberg, J. P., & Roopenian, D. C. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19960117)65:2<204::aid-ijc13>3.0.co;2-d · Cited by 18
Baxevanis, C. N. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02335-7 · Cited by 14 · cited 1×
“The immune system can confine the metastatic spread of cancer cells, encouraging their long-lasting latency [104].”
BackgroundBakács, T., & Mehrishi, J. N. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-251 · Cited by 10 · cited 3×
“Dormancy state induced by the elimination of primary tumor can be avoided by a ‘recombinant T cell receptor ligand therapy’, dosing days in advance to tumor resection and lasting throughout the whole treatment course, that is a highly speculative therapy [43].”
BackgroundInfluentialImmunotherapy of Cancer: Targeting Cancer During Active Disease or During Dormancy?
Shah, S. A., Zarei, M., Manjili, S. H., Guruli, G., Wang, X., & Manjili, M. H. (2017) · Immunotherapy · doi:10.2217/imt-2017-0044 · Cited by 10
Self-citationMima, S., Kakinuma, C., Higuchi, T., Saeki, K., Yamada, T., Uematsu, R., Ishino, M., 鬼頭, 信., Nishikawa, H., Kuniyoshi, H., et al. (2018) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.248740 · Cited by 10 · cited 1×
“Another study has shown the superior performance of FF-10502, a pyrimidine nucleoside antimetabolite over gemcitabine on pancreatic dormant cells, by inducing dormant cell injury in chemotherapy-resistant cells through blocking with DNA polymerase β activity and DNA repair [59].”
BackgroundYang, L., Shan, Y., Zhang, Y. Q., Zhou, E., Chen, X., & Zhang, H. (2019) · Head & Neck · doi:10.1002/hed.25689 · Cited by 9
Quiescence-like Metabolism to Push Cancer Out of the Race
Torrano, V., & Carracedo, A. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.04.027 · Cited by 8 · cited 1×
“These models were somewhat successful in recapitulating dormancy mechanism of tumors, as they lead to the discovery of cellular dormancy factors/mechanisms including extracellular matrix (ECM) [10], metabolic [11,12], epigenetic [13,14], stemness [15,16], non-coding RNAs [17], and p38 stress-induced signaling pathway…”
BackgroundDatasets describing hydrogel properties and cellular metrics for modeling of tumor dormancy
Pradhan, S., & Slater, J. H. (2019) · Data in Brief · doi:10.1016/j.dib.2019.104128 · Cited by 7
A Marker for Dormant Cancer Stem Cells in Human Hepatocellular Carcinoma
Marusawa, H., & Chiba, T. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.039 · Cited by 6
Sinha, G., & Rameshwar, P. (2015) · Cell death in therapy · doi:10.1515/cdth-2015-0002 · Cited by 4
Tumor Cell Dormancy: How It Performs in Drug Resistance and Relapse
Dai, Y., & Jj, X. (2018) · Lanzhou University Institutional Repository · doi:10.16476/j.pibb.2017.0389 · Cited by 4 · cited 1×
“After cessation of the therapy, the dormant cells may repopulate, resulting in tumor recurrence and development of chemotherapyresistant cancer cells [2,3].”
BackgroundProlonged dormancy of human liposarcoma is associated with impaired tumor angiogenesis
(2006) · The FASEB Journal · doi:10.1096/fasebj.20.9.1573-d · Cited by 4
Cited by
Tumor microenvironment complexity and therapeutic implications at a glance
Baghban, R., Roshangar, L., Jahanban-Esfahlan, R., Seidi, K., Ebrahimi-Kalan, A., Jaymand, M., Kolahian, S., Javaheri, T., & Zare, P. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-0530-4 · Cited by 1,784
“2e) [9] .”
BackgroundSelf-citationThe lingering mysteries of metastatic recurrence in breast cancer
Riggio, A. I., Varley, K. E., & Welm, A. L. (2021) · British Journal of Cancer · doi:10.1038/s41416-020-01161-4 · Cited by 616
“Cellular and tumour mass dormancy Two different models of tumour dormancy—cellular and tumour mass dormancy—have been proposed.(75) Cellular dormancy refers to the presence of solitary or small cell clusters of DTCs that exist in a G0/G1 growth-arrested state(63) and result from quiescence,(84) senescence or different…”
BackgroundAspects of the Tumor Microenvironment Involved in Immune Resistance and Drug Resistance
Khalaf, K., Hana, D., Chou, J. T.-T., Singh, C., Mackiewicz, A., & Kaczmarek, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.656364 · Cited by 513
Cancer Stem Cells—Key Players in Tumor Relapse
Marzagalli, M., Fontana, F., Raimondi, M., & Limonta, P. (2021) · Cancers · doi:10.3390/cancers13030376 · Cited by 161
“The dormant state can be acquired by cancer cells not only following the exposure to drugs, but also in order to colonize and adapt to distant organs, and then give rise to metastasis (disseminated tumor cells, DTCs) [68].”
BackgroundGisbert-Garzarán, M., Manzano, M., & Vallet‐Regí, M. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12010083 · Cited by 149
“These cells are clinically undetectable and, consequently, constitute a major issue for future tumor recurrence and metastases [100].”
Background
Metadata
- Authors
- Jahanban-Esfahlan, R., Seidi, K., Manjili, M. H., Jahanban-Esfahlan, A., Javaheri, T., & Zare, P.
- Affiliations
- Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz 9841, Iran
- Tabriz University of Medical Sciences (IR)
- Virginia Commonwealth University (US)
- Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz 9841, Iran
- Ludwig Boltzmann Institute for Cancer Research (AT)
- Faculty of Medicine, Cardinal Stefan Wyszyński University in Warsaw, 01-938 Warsaw, Poland
- Corresponding author
- Javaheri, Tahereh
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2019-08-19
- Volume
- 11
- Issue
- 8
- Pages
- 1207
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC6721805
- OpenAlex
- W2897235350
- Cited by
- 111
- References
- 140
- Citations by year
- 2026: 8 · 2025: 16 · 2024: 7 · 2023: 13 · 2022: 19 · 2021: 21 · 2020: 25 · 2019: 1
- FWCI
- 1.57
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mechanisms of cancer metastasis
- Physical Sciences › Mathematics › Modeling and Simulation › Mathematical Biology Tumor Growth
- Keywords
- tumor dormancy, tumor recurrence, metastasis, multidrug resistance, minimal residual disease, angiogenic switch, immune evasion, cancer stem cells, extracellular matrix remodeling, metabolic reprogramming, microRNA, epigenetic modifications, p38 signaling, cancer prognosis, cancer therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.


